Skip to main content

Topic

Intended Use

7 published works

  1. Health Care and Life Sciences

    FDA Maintains Focus on “Intended Use” for Software-Enabled Medical Devices

    By Dominick DiSabatino, Audrey Mercer, Julian Klein

    On June 21, 2023, the U.S. Food and Drug Administration (“FDA”) issued a warning letter to Zyto Technologies, Inc. (“Zyto”), citing Zyto’s promotion of its Hand Cradle Galvanic Skin Response…

  2. Drug & Device Law

    FDA Completes “Intended Use” Administrative Marathon

    By Bexis

    Nearly six years ago, in 2015, the FDA attempted to slip a change to its “intended use” regulations (21 C.F.R. §§201.128, 801.4) – which had not been updated since the…

  3. Drug & Device Law

    FDA’s Latest Attempt to Update “Intended Use” Regulations

    By Bexis

    When we last examined the FDA’s sporadic effort to update the archaic “intended use” regulations (primarily 21 C.F.R. §§201.128 (drugs), 801.4 (devices)), the 2017 bait-and-switch amendment to these regulations had…

  4. Drug & Device Law

    FDA Proposes to Delay Off-Label “Intended Use” Rule

    By Stephen McConnell

    Perhaps you have heard that elections have consequences. That is true not only for high-profile issues that hog the headlines on CNN and Fox News, but it is also true…

  5. Drug & Device Law

    The Rule of Law is the Best Medicine, Part 2

    By Stephen McConnell

    Last week, we summarized PhRMA’s comments on the FDA’s proposed amendments to regulations regarding “intended uses.”  PhRMA showed how the FDA’s insistence that it could read manufacturer’s minds about intended…

  6. Focus on Regulation

    KNOWLEDGE ALONE ≠ INTENT: FDA Proposes To Trim One Basis for Determining “Intended Use” of Drugs and Devices

    By Susan Lee, Jennifer Agraz Henderson

    Last week, the U.S. Food and Drug Administration (FDA) published a proposed rule, 80 Fed. Reg. 57756 (Sept. 25, 2015), that at first blush is devoted to clarifying when a…

  7. Drug & Device Law

    Knowledge and Intended Use

    By Bexis

    Our post last week on the three-ringed FCA circus in U.S. v. King Vassel, got us thinking about another way that misguided plaintiffs try to criminalize off-label use.  Deviating from the…